Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

MDxHealth SA MDXH

Healthcare  —  Diagnostics & Research
0.57 (0.01) (1.72%) as of 25 Sep
Market cap
$55.5M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

MDxHealth SA (MDXH) Business Profile

Updated before January 2025

Company Overview

MDxHealth SA (MDXH) is a leading molecular diagnostics company specializing in the development and commercialization of advanced epigenetic and molecular diagnostic solutions. Founded in 2003 and headquartered in Herstal, Belgium, MDxHealth has established itself as a pioneer in the field of precision medicine, particularly in the diagnosis and management of urological cancers. The company operates globally, with a strong presence in the United States and Europe.

MDxHealth’s leadership team comprises experienced professionals from the biotechnology and healthcare sectors. The company’s CEO, Michael K. McGarrity, brings extensive expertise in diagnostics and healthcare innovation. Under his leadership, MDxHealth has focused on expanding its product portfolio and strengthening its market position.

Core Business Segments

MDxHealth’s core business revolves around molecular diagnostics, with a primary focus on urological cancers. The company’s product offerings are categorized into the following segments:

1. Prostate Cancer Diagnostics

  • ConfirmMDx® for Prostate Cancer: A tissue-based epigenetic test that helps identify patients at risk of undetected prostate cancer, reducing unnecessary repeat biopsies.
  • SelectMDx® for Prostate Cancer: A non-invasive urine-based test that assesses the risk of aggressive prostate cancer, aiding in early detection and treatment decisions.

2. Bladder Cancer Diagnostics

  • AssureMDx® for Bladder Cancer: A urine-based test designed to detect bladder cancer recurrence in patients with a history of the disease. This test improves patient monitoring and reduces the need for invasive procedures.

3. Other Molecular Diagnostic Services

MDxHealth also offers laboratory services and custom diagnostic solutions to healthcare providers and research institutions. These services leverage the company’s expertise in epigenetics and molecular biology.

Business Model

MDxHealth operates on a business model that integrates innovative diagnostic products with comprehensive laboratory services. The company generates revenue through the sale of its proprietary diagnostic tests, laboratory testing services, and licensing agreements. Key elements of its business model include:

  • Product Commercialization: MDxHealth markets its diagnostic tests directly to healthcare providers and through strategic partnerships with laboratories and distributors.
  • Laboratory Services: The company operates certified laboratories that process diagnostic tests and provide results to clinicians.
  • Licensing and Collaborations: MDxHealth collaborates with pharmaceutical companies and research institutions to develop and commercialize new diagnostic solutions.

Strategic Direction

MDxHealth is committed to advancing precision medicine through innovation and strategic growth. Key elements of the company’s strategic direction include:

  • Expansion of Product Portfolio: MDxHealth aims to develop new diagnostic tests for additional cancer types and other diseases, leveraging its expertise in epigenetics.
  • Geographic Expansion: The company is focused on increasing its presence in key markets, particularly in North America and Europe.
  • Sustainability Goals: MDxHealth is dedicated to minimizing its environmental impact by adopting sustainable practices in its operations and supply chain.
  • Digital Transformation: The company is investing in digital technologies to enhance its diagnostic capabilities and improve patient outcomes.

Competitive Landscape

MDxHealth operates in a competitive market, facing competition from both established players and emerging companies in the molecular diagnostics space. Key competitors include:

  • Exact Sciences Corporation: Known for its Cologuard® test for colorectal cancer, Exact Sciences is a major player in the molecular diagnostics market.
  • Myriad Genetics: A leader in genetic testing and precision medicine, Myriad Genetics offers a range of diagnostic solutions for cancer and other diseases.
  • Genomic Health (now part of Exact Sciences): Specializes in genomic-based diagnostic tests for cancer.
  • Bio-Techne Corporation: Provides advanced diagnostic and research tools, including molecular diagnostic solutions.

MDxHealth differentiates itself through its focus on epigenetics and its comprehensive approach to urological cancer diagnostics.

Risk Factors

MDxHealth faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its prostate and bladder cancer diagnostic tests. Any decline in demand for these products could affect revenue.
  • Regulatory Challenges: As a diagnostics company, MDxHealth must comply with stringent regulatory requirements, which can be time-consuming and costly.
  • Supply Chain Disruptions: The company’s operations depend on a reliable supply chain for raw materials and laboratory equipment. Disruptions could delay product delivery and impact customer satisfaction.
  • Competition: Intense competition in the molecular diagnostics market could pressure pricing and market share.
  • Economic Factors: Changes in healthcare policies, reimbursement rates, and economic conditions could affect the adoption of MDxHealth’s products.

Recent Developments

MDxHealth has made significant strides in recent years, including:

  • Launch of New Products: The company introduced updated versions of its diagnostic tests, incorporating advanced technologies to improve accuracy and ease of use.
  • Strategic Partnerships: MDxHealth entered into collaborations with leading laboratories and healthcare providers to expand its market reach.
  • Regulatory Approvals: The company received regulatory clearances for its diagnostic tests in key markets, enabling broader adoption.
  • COVID-19 Impact: The pandemic highlighted the importance of non-invasive diagnostic solutions, driving demand for MDxHealth’s products.

Investment Considerations

Investors considering MDxHealth should weigh the following factors:

Strengths

  • Innovative Product Portfolio: MDxHealth’s focus on epigenetics and molecular diagnostics positions it as a leader in precision medicine.
  • Growing Market: The demand for non-invasive diagnostic solutions is increasing, driven by advancements in technology and a focus on early disease detection.
  • Strong Leadership: The company’s experienced management team provides strategic direction and operational expertise.

Risks

  • Market Dependence: Reliance on a limited number of products could pose a risk if market conditions change.
  • Regulatory Hurdles: Compliance with regulatory requirements can be challenging and costly.
  • Competition: Intense competition in the molecular diagnostics market could impact profitability.

Conclusion

MDxHealth SA is a leading player in the molecular diagnostics market, with a strong focus on urological cancers. The company’s innovative product portfolio, strategic growth initiatives, and commitment to precision medicine position it for long-term success. While challenges such as market dependence and regulatory hurdles exist, MDxHealth’s strengths and growth potential make it an attractive option for investors and healthcare providers alike.